



BREACH
BELGIAN RESEARCH AIDS&HIV CONSORTIUM

BREACH ACTIVITIES : An Update

Prof. Stéphane DE WIT
Chair

BREACH Research Activities Pipeline

Manuscripts in preparation

- “Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real-world setting in Belgium”

Ongoing projects

- “A retrospective, observational, multicenter study on the efficacy and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV”
 - Estimated study completion date: March 2022

Upcoming studies

- “A characterization of the HIV population in Belgium with limited treatment options”
 - The objective of this study is to explore the prevalence and characteristics of the Belgian HIV patient population who have limited treatment options because of documented resistance or a history of being heavily treatment experienced.
 - Planned start date: January 2022
- “Women living with HIV in Belgium: A cross-sectional study”
 - The objective is to describe the demographic, HIV-, and non-HIV-related characteristics of WLWH in Belgium in order to subsequently address the specific medical needs of this population.
 - Planned start date: Q2 2022

Studies in preparation

- Cabotegravir-based 2DR real-world study

King Baudouin Foundation (KBF) and the Belgian HIV Research Consortium (BREACH) Collaboration

- KBF and BREACH have agreed to put in place a collaborative process aiming to pursue the optimal utilization of the KBF AIDS Fund in the coming years.
- Support to research projects on HIV / AIDS in Belgium
- Calls will be every 2 years and will alternatively focus on Basic Science, Clinical Science and Public Health / Epidemiology
- First call in January 2022 on Basic Science
- Support : 200 000 Euros + contribution from the industry still in discussion.

Next Spring Meeting 2022 in May on

5 years of PrEP in Belgium